Alector, Inc. (CIK: 0001653087) filed an 8-K with the SEC on October 14, 2026, detailing significant changes to its stock option program. This filing is important for investors and employees alike, as it reflects the company's strategy to retain talent and manage its equity compensation amid challenging market conditions.
Alector, Inc. is a biotechnology company based in South San Francisco, California, focused on developing therapies for neurodegenerative diseases. The 8-K form is used by publicly traded companies to report major events that shareholders should know about, providing transparency regarding corporate actions.
Details of the Filing
The filing highlights that on October 13, 2026, Alector's Board of Directors approved a repricing of stock options. This decision affects options granted under the company's 2019 Equity Incentive Plan and the 2017 Stock Option and Grant Plan. The repricing applies to options held by current employees that had an exercise price greater than $1.87, which is the new exercise price set for these options.
Notably, the repriced options include those held by key executives, including Arnon Rosenthal, Ph.D., the Co-founder and CEO, and Grace Wong-Sarad, the Chief Accounting Officer. Dr. Rosenthal has options to purchase 2,421,197 shares, while Wong-Sarad holds options for 87,385 shares. The original exercise prices for these options ranged from $6.48 to $23.70 per share.
The filing states, "The new exercise price for repriced options is $1.87 per share, the closing price of the Company’s common stock on the Effective Date." However, if an employee exercises a repriced option before the end of a defined Retention Period, they must pay a premium equal to the original exercise price.
The Retention Period is defined as the time frame starting from the repricing date until one year later, or until a change in control occurs, or the option holder's death or disability.
Impact of the Repricing
This repricing may significantly impact Alector's employees, particularly those with underwater options. As of the date of the repricing, many employees held options with exercise prices above the current market price, making them less valuable. By lowering the exercise price, Alector aims to motivate and retain its workforce, which is crucial for the company's ongoing projects and overall stability.
Moreover, the decision to reprice rather than issue new equity grants or cash bonuses is a strategic move to minimize stock dilution and cash expenditure. The total number of shares affected by this repricing is approximately 4.05 million, indicating a substantial commitment to retaining talent.
What's Next
The filing does not specify what happens next regarding the repricing or any further actions by the company. Investors and employees will likely be watching closely to see how this decision affects Alector's performance and employee morale in the coming months.